Trulicity Guide
Trulicity is the brand-name formulation of dulaglutide, a once-weekly subcutaneous GLP-1 receptor agonist. The FDA has approved it on two counts, both confined to type 2 diabetes in adults: glycemic control, and cardiovascular risk reduction where the patient already has established cardiovascular disease or several cardiovascular risk factors. Manufactured by Eli Lilly, Trulicity was the first GLP-1 to show a CV benefit in a primary-prevention diabetes population (REWIND, 2019). It has never had an obesity indication — average weight loss in trials is modest at roughly 3–5 kg — and Wegovy and Zepbound dominate the chronic weight management category.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Dulaglutide |
| Brand Names | Trulicity |
| FDA Status | FDA-approved for glycemic control in adults with type 2 diabetes mellitus (September 18, 2014); FDA-approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established CVD or multiple cardiovascular risk factors (February 2020); pediatric indication for type 2 diabetes in patients aged 10 years and older added in 2022. Not approved for chronic weight management.[1] |
| Approval Date | September 18, 2014[1] |
How does Trulicity work?
Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing two modified GLP-1 peptide chains to a human IgG4 Fc fragment, which extends the half-life to about five days and allows once-weekly dosing. By activating GLP-1 receptors, dulaglutide stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and modestly reduces appetite. The blood-sugar-lowering effect is the labeled indication; the weight reduction is a secondary effect that is smaller than what is seen with semaglutide or tirzepatide.[2]
Dosing Schedule
Trulicity uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
What side effects does Trulicity cause?
Common: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia, fatigue. Side effects are most pronounced during dose initiation and escalation, and typically diminish over 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease (cholecystitis, cholelithiasis), acute kidney injury (often secondary to dehydration from GI side effects), severe hypoglycemia when combined with insulin or sulfonylureas, hypersensitivity reactions, diabetic retinopathy complications. Boxed warning for thyroid C-cell tumors observed in rodents; contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
The AWARD program comprised the pivotal phase 3 trials supporting Trulicity's approval and label expansions, evaluating dulaglutide as monotherapy and in combination with metformin, sulfonylureas, insulin, and SGLT2 inhibitors across more than 10 studies. AWARD-7 (Tuttle et al. Lancet Diabetes Endocrinol 2018, PMID 29910024) took patients who had type 2 diabetes alongside chronic kidney disease of moderate-to-severe grade, and found dulaglutide noninferior to insulin glargine on HbA1c reduction while causing less weight gain and less hypoglycemia. SUSTAIN-7 (Pratley et al. Lancet Diabetes Endocrinol 2018, PMID 29397376) set once-weekly semaglutide against dulaglutide head to head: at matched dose levels semaglutide cut HbA1c further and body weight further. REWIND, the landmark cardiovascular outcomes trial (Gerstein et al. Lancet 2019, PMID 31189511), randomized 9,901 type 2 diabetes patients — most without established CVD — and showed a 12% relative reduction in major adverse cardiovascular events with dulaglutide 1.5 mg over a median follow-up of 5.4 years (HR 0.88, 95% CI 0.79–0.99). REWIND remains the largest and longest GLP-1 CVOT and the first to demonstrate CV benefit in a primary-prevention diabetes population, though the effect size was the smallest in the GLP-1 CVOT class.[2]
Where can you get Trulicity?
No seller in our register lists Trulicity with a price. It is filled by retail pharmacies on a prescription. The Trulicity cost page has what the manufacturer charges.
How much does Trulicity cost?
No seller in the register publishes a price for Trulicity. An FSA or HSA will generally cover the prescription under IRS Publication 502[3].
Trulicity Head-to-Head Comparisons
Short verdict pages setting Trulicity against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Pivotal Trulicity Trial Walkthroughs
The trials that produced the Trulicity label, taken endpoint by endpoint, with the figures read off the source.
Ranked PubMed Studies on Trulicity
The peer-reviewed studies on Trulicity and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.
Related Research on Trulicity
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 3.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.